Loading
A phase 1 trial of HLD-0915 (JNJ-101556143) run by Janssen Research & Development, LLC, now recruiting.
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer is a phase 1 interventional study registered as NCT06095089 by Janssen Research & Development, LLC, with 355 participants planned, started 2023-11-01. Conditions recorded: Prostatic Neoplasms. Interventions recorded: JNJ-78278343, JNJ-87189401, Apalutamide, Lutetium Lu-177 Vipivotide Tetraxetan and JNJ-101556143.
Shares HLD-0915 (JNJ-101556143), Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/